Hypercalcemia of malignancy: Patomechanism, symptoms and treatment

Onkologia Polska

Volumn 14, Issue 2, 2011, Pages 103-106

  Szyszka Barth, Katarzyna ^a   Spychalski, Łukasz ^a   Hałas, Joanna ^a   Bryl, Maciej ^a   Ramlau, Rodryg ^a  

^a Department of Clinical Oncology   (Poland)

Author keywords

Bisphosphonates; Calcitonin; Hypercalcemia; Malignant neoplasm

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; ETIDRONIC ACID; GALLIUM NITRATE; MITHRAMYCIN; PAMIDRONIC ACID; PREDNISOLONE; ZOLEDRONIC ACID;

BLEEDING; BONE PAIN; CONTINUOUS INFUSION; DIARRHEA; ELECTROLYTE DISTURBANCE; FATIGUE; FEVER; FLU LIKE SYNDROME; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; LIVER TOXICITY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NAUSEA; OSTEOLYSIS; PATHOGENESIS; REVIEW; SIDE EFFECT; SKIN REDNESS; TACHYPHYLAXIS; VOMITING;

EID: 80054886252     PISSN: 15056732     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Warren R.P.: Metabolic Emergencies. [in:] Cancer. Principles and practice of oncology. V.T. De Vita Jr., S. Hellman, S.A. Rosenberg (ed.), Lippincott-Raven Publishers, Philadelphia 1997.
2. Krzakowski M., Pieńkowski T.: Zaburzenia metaboliczne i wodno-elektrolitowe u chorych na nowotwory. [in:] Onkologia kliniczna. M. Krzakowski (ed.). Borgis, Warszawa 2006.
3. Virchow R.: Kalk-Metastases. Virchows Arch. (Pathol. Anat.), 1855, 8, 103.
4. Albright F.: Case records of the Massachusetts General Hospital, case 27461. N. Engl. J. Med., 1941, 225, 789.
5. Kokot F., Franek F.: Zaburzenia gospodarki wapniowo-fosforanowej. [in:] Choroby wewnȩtrzne. Stan wiedzy na rok 2010. A. Szczeklik (ed.). Medycyna Praktyczna, Kraków 2010, 2244-2248.
6. Iqubal S.J., Giles M., Ledger S. et al.: Need for albumin adjustments of urgent total serum calcium. Lancet, 1998, 2, 1477-1478.
7. Trice E., Hochberg E.P.: Stany zagrożenia w onkologii zwia̧zane z zaburzeniami metabolicznymi. [in:] Harrison. Onkologia. B.A. Chabner, T.J. Lynch, D.L. Longo (ed.), D. Perek (Polish ed.), Czelej, Lublin 2009, 115-128.
8. Azzopardi J.G., Whittaker R.S.: Bronchial carcinoma and hypercalcaemia. J. Clin. Path., 1969, 22, 718-724.
9. Ralston S.H., Fogelman I., Gardiner M., Boyle I.: Relative contribution of humoral and metastatic factors to the patogenesis of hypercalcaemia in malignancy. Br. Med. J., 1984, 288, 1405-1408. (Pubitemid 14088432)
10. Gilmore J.L., Gonterman R.M., Menon K. et al.: Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone. Mol. Cancer Res., 2009, 7, 1714-1728.
11. Burzyantseva O., Dharmasena S., Jayawardena S. et al.: Hypercalcemia-leukocytosis syndrome in a patient with cavitating squamous cell carcinoma of the lung. Cases J., 2009, 2, 1-4.
12. Murray T.M., Josse R.G., Heersche J.N.M.: Hypercalcemia and cancer: an update. Can. Med. Assoc. J., 1978, 119, 915-919.
13. Ralston S.H.: Medical management of hypercalcemia. Br. J. Pharmac., 1992, 34, 11-20.
14. Bilezikian J.: Clinical review 51: management of hypercalcemia. J. Clin. Endocrinal. Metab., 1993, 77, 1445-1449.
15. Drake M., Clarke B., Khosla S.: Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc., 2008, 83, 1032-1045.
16. Polascik T.J.: Bisphosphonates in oncology: evidence of the prevention of skeletal events in patients with bone metastases. Drug. Des. Devel. Ther., 2009, 3, 27-40.
17. Kearney T., Dang C.: Diabetic and endocrine emergencies. Postgrad. Med., 2007, 83, 79-86. (Pubitemid 46340334)
18. Body J.J., Borkowski A., Cleeren A. et al.: Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J. Clin. Oncol., 1986, 4, 177-183.
19. Almubarak H., Jones A., Chaisuparat R., Zhang M. et al.: Zoledronic acid directly supresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancer. J. Carcinog., 2011, 10, 1-10.
20. Drudge-Coates L.: Improving management of patients with advanced cancer. Patient Prefer. Adherence, 2010, 4, 415-424.
21. Orzechowska-Juzwenko K.: Leki przeciwnowotworowe. [in:] Farmakologia. Podstawy farmakoterapii. W. Kostowski, Z.S. Herman (ed.), PZWL, Warszawa 2005, 400-444.
22. Godfrey T., Linda L.: Mithramycin for hypercalcemia of malignant disease. Calif. Med., 1971, 115, 1-4.
23. Da̧browski T.: Aspekty zastosowania wybranych zwia̧zkó w metali w terapii przeciwnowotworowej. Wspołcz. Onkol., 1999, 6, 249-252.
24. Christopher C.R.: Medical applications and toxicities of gallium compounds. Int. J. Environ. Res. Public Health, 2010, 7, 2337-2361.
25. Hosking D.J., Gilson D.: Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcemia of malignancy. Quart. J. Med. 1984, 211, 359-368. (Pubitemid 14004816)
26. Ljunghall S.: Use of clodronate and calcitonin in hypercalcemia due to malignancy. Recent results. Cancer Res., 1989, 116, 40-45.
27. Fulmer D.H., Dimich A.B., Rotschild E.O., Myers W.P.L.: Treatment of hypercalcaemia: comparison of intravenously administrated phosphate, sulphate and hydrocortisone. Arch. Intern. Med., 1972, 129, 923-930.